Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2023 CCM–CARE Act of 2023
Impact
The bill proposes establishing a national framework for addressing CCM through increased coordination between various federal health research agencies, including the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). It mandates comprehensive research activities focusing on early detection methods, effective treatment solutions, and improving the quality of life for patients with CCM. The introduction of a national surveillance program for CCM would enable more efficient data collection and analysis regarding its prevalence and clinical implications, directly influencing public health policies and funding allocation.
Summary
SB543, also known as the 'Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2023' or 'CCM–CARE Act of 2023', aims to enhance the awareness, research, and treatment options available for cerebral cavernous malformations (CCM). This bill recognizes that CCM, a condition characterized by abnormal blood vessel formations in the brain and spinal cord, affects approximately 600,000 individuals in the U.S., though only a fraction are diagnosed. The legislation seeks to address existing gaps in treatment, awareness, and research funding, especially given that current treatment options are limited mainly to surgical interventions.
Contention
Debate surrounding SB543 centers on the adequacy of funding for the proposed initiatives and the prioritization of CCM research compared to other health conditions. Proponents argue that the lack of treatment options and awareness necessitates immediate action, while critics voice concerns over resource allocation and whether CCM should be a priority at a national level, considering the breadth of other pressing health issues. Additionally, the bill's provisions for training healthcare professionals to better manage CCM may raise concerns regarding the feasibility and speed of such training at a time of high demand for medical resources.
Triple-Negative Breast Cancer Research and Education Act of 2023 This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors. Specifically, the National Institutes of Health must conduct and support research into the disease. Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.